Monte Rosa Therapeutics (GLUE) Interest Expenses (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Interest Expenses of $122.6 million for Q1 2026, up 1566.3% year-over-year from $7.4 million in Q1 2025, and up 6.42% quarter-over-quarter from $115.2 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Interest Expenses (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $122.6 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 1566.3% year-over-year to $122.6 million; the TTM figure through Mar 2026 stood at $122.6 million (up 1566.3% YoY), while the FY2025 annual figure was $115.2 million, up 59.71% from the prior year.
- Interest Expenses for Q1 2026 stood at $122.6 million, up from $115.2 million in the prior quarter.
- The five-year high for Interest Expenses was $122.6 million in Q1 2026, with the low at $7.4 million in Q1 2025.
- The 5-year median for Interest Expenses is $54.5 million (2023), against an average of $50.8 million.
- The sharpest annual moves came in 2025 and 2026: Interest Expenses tumbled 89.05% in 2025, then surged 1566.3% in 2026.
- Monte Rosa Therapeutics' Interest Expenses stood at $12.4 million in 2022, then soared by 337.82% to $54.5 million in 2023, then slumped by 79.03% to $11.4 million in 2024, then soared by 909.24% to $115.2 million in 2025, then advanced by 6.42% to $122.6 million in 2026.
- Business Quant data shows GLUE's Interest Expenses at $122.6 million in Q1 2026, $115.2 million in Q4 2025, and $15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 239.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.64 Mn |
| Jun 30, 2026 | 239.64 Mn |
| Mar 31, 2026 | 122.64 Mn |
| Mar 31, 2026 | 122.64 Mn |
| Dec 31, 2025 | 115.25 Mn |
| Dec 31, 2025 | 115.25 Mn |
| Sep 30, 2025 | 15.85 Mn |
| Sep 30, 2025 | 15.85 Mn |
| Jun 30, 2025 | 57.97 Mn |
| Jun 30, 2025 | 57.97 Mn |
| Mar 31, 2025 | 7.36 Mn |
| Mar 31, 2025 | 7.36 Mn |
| Dec 31, 2024 | 11.42 Mn |
| Dec 31, 2024 | 11.42 Mn |
| Sep 30, 2024 | 19.90 Mn |
| Sep 30, 2024 | 19.90 Mn |
| Jun 30, 2024 | 20.95 Mn |
| Jun 30, 2024 | 20.95 Mn |
| Mar 31, 2024 | 67.22 Mn |
| Mar 31, 2024 | 67.22 Mn |